WHO ICTRP trial
A clinical trial to study the effect of olanzapine in patients receiving highly…
CTRI/2019/01/017317 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2019/01/017317 |
|---|---|
| Public title | A clinical trial to study the effect of olanzapine in patients receiving highly emetogenic chemotherapy |
| Scientific title | Efficacy and safety of olanzapine as an add on therapy in children receiving highly emetogenic chemotherapy: A Randomized Double Blind Placebo Controlled Trial |
| Primary sponsor | All India Institute of Medical Sciences |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue |
| Interventions | Intervention1: Olanzapine: Patients in the intervention group will receive oral olanzapine once daily (0.15 mg/kg/dose) 45 min prior to chemotherapy on Day 1 and 24 hours after the first dose on day 2. Control Intervention1: Placebo… |
| Registration date | Jan 31, 2019 |
| Target size | 128 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: